You are currently viewing Craif Secures 22 Million in Series C Funding to Revolutionize Early Cancer Detection

Craif Secures 22 Million in Series C Funding to Revolutionize Early Cancer Detection

Prime Highlights:

  • Craif raises Series C funding of $22M for growing U.S. presence and R&D activities.
  • Company builds non-invasive urine test based on microRNA for cancer detection.

Key Facts:

  • Valuation of Craif rises to about $100 million following Series C funding.
  • Total funding raised by the company to date is $57 million.

Key Background:

Craif Inc., established as a start-up firm in 2018 in Tokyo, came up with a revolutionary platform for the early detection of cancer by utilizing microRNA (miRNA) biomarkers in urine. The new technology provides a low-cost, cost-effective, and non-invasive method compared to conventional diagnostic tests, such as blood tests or imaging tests. Craif’s technology employs nanowire devices to trap exosomes from filtered urine samples based on artificial intelligence to identify cancer at its initial stage.

The “miSignal” test is the flagship product of the company and has been formulated to identify multiple cancers such as pancreatic, lung, and breast cancer. As compared to cfDNA based regular tests, the technology of Craif targets miRNA, which is released by cancer cells at an early stage, thus it is a suitable early diagnosis biomarker. Urine use as the source of sample also increases test convenience since it is less intrusive and can be conducted at home, thus lowering patient distress and increasing access to screening.

Craif’s continued commitment to innovation and excellence has been recognized in numerous awards and partnerships. In 2024, the firm was selected to participate in the very competitive Medtech Innovator Accelerator Cohort, the global largest medtech accelerator of medical device, diagnostic, and digital health start-ups. It is a reflection of the company’s ability to transform cancer detection and improve patient outcomes worldwide.

With the Series C financing, Craif will increase its presence in the United States and reach more people with its lifesaving technology. The company’s mission is consistent with the increasing focus on personalized medicine and preventive care, and Craif is poised at the forefront of the battle against cancer.

Read Also : New Research Suggests Shingles Vaccine May Help Prevent Dementia